melanocortin receptors is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-14. Numbers and descriptions here follow the published literature rather than marketing material.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
| Molecular weight | Approximately 1024 g/mol | Calculated for the free base |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and polar solvents | Poorly soluble in non-polar solvents |
| Typical storage | -20 degrees Celsius, dry, protected from light | Refers to the solid form |
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
That is how this entire mass of suffering originates.The Mahahatthipadopama-sutta (M 28) contains another short explanation of dependent origination:these five grasping aggregates are indeed dependently originated. The desire, adherence, attraction, and attachment for these five grasping aggregates is the origin of suffering. Giving up and getting rid of desire and greed for these five grasping aggregates is the cessation of suffering.
== Mutation studies == Many P-type calcium channels mutations result in a decreased level of intracellular free calcium. Maintaining calcium homeostasis is essential for normally functioning neurons. Changing the cellular calcium ion concentration acts as a trigger for multiple diseases, in severe cases these diseases can result in mass neuronal death. Mutation studies allow experimenters to study genetically inherited channelopathies. A channelopathy is any disease that results from an ion channel with malfunctioning subunits or regulatory proteins. One example of a P-type calcium channel channelopathy is shown in homozygous ataxic mice, who are recessive for both the tottering and leaner genes. These mice present with mutations in the alpha1A subunit of their P/Q type channels. Mutations in these channels result in deficiencies within the cerebellar Purkinje cells that dramatically reduce the channels current density. The tottering mutations within mice result from a missense mutation and causes delayed-onset of seizures and ataxia. The tottering mutation substitutes a single proline instead of a leucine within the P-region of the channel. The P-region is responsible for the formation of the ion channel pore. The leaner mutation, which results in more severe symptoms than the tottering mutation, has been shown to result from a single nucleotide substitution that causes splicing failures within the channels open reading frame.
SLC7A11 is a member of a heterodimeric Na+-independent anionic amino acid transport system highly specific for cystine and glutamate. This antiporter imports cystine and exports glutamate, which are both amino acids. An antiporter functions with a one-to-one counter-transport, which is when one substance is transported across the membrane at the same time another substance is transported across the membrane in the opposite direction. The antiporter is a heterodimeric amino acid transporter, requiring both the SLC7A11 light chain and SLC3A2 heavy chain linked by a disulfide bridge. The SLC7A11 light chain has 12 transmembrane domains consisting of 501 amino acids, and the SLC3A2 heavy chain appears to be highly conserved among transporters. The human SLC7A11 has an 89% similarity of amino acids to the homologous mouse xCT protein. The complementary DNA, cDNA, has a total of 9648 base pairs. The SLC7A11 gene has been found not only in the brain, but has also been found to be expressed in the spinal cord, pancreas, and in glioma cells.
Chemiosmosis is the movement of ions across a semipermeable membrane through an integral membrane protein, down their electrochemical gradient. An important example is the formation of adenosine triphosphate (ATP) by the movement of hydrogen ions (H+) through ATP synthase during cellular respiration or photophosphorylation.
Sources: en.wikipedia.org
== Epidemiology == Pooled data suggest the incidence of NMS is between 0.2%–3.23%. However, greater awareness coupled with increased use of atypical anti-psychotics have likely reduced the prevalence of NMS. Additionally, young males are particularly susceptible and the male to female ratio has been reported to be as high as 2:1.
Controversy exists as to whether some of these treatments should be acceptable, but one can be more or less forgiven universally: This is the light waxing or oiling applied to most gem turquoise to improve its colour and lustre; if the material is of high quality to begin with, very little of the wax or oil is absorbed and the turquoise therefore does not rely on this impermanent treatment for its beauty. All other factors being equal, untreated turquoise will always command a higher price. Bonded and reconstituted material is worth considerably less. Being a phosphate mineral, turquoise is inherently fragile and sensitive to solvents; perfume and other cosmetics will attack the finish and may alter the colour of turquoise gems, as will skin oils, as will most commercial jewellery cleaning fluids. Prolonged exposure to direct sunlight may also discolour or dehydrate turquoise. Care should therefore be taken when wearing such jewels: cosmetics, including sunscreen and hair spray, should be applied before putting on turquoise jewellery, and they should not be worn to a beach or other sun-bathed environment. After use, turquoise should be gently cleaned with a soft cloth to avoid a buildup of residue, and should be stored in its own container to avoid scratching by harder gems. Turquoise can also be adversely affected if stored in an airtight container.
Compounds containing one or more elements which can exist in a variety of charge/oxidation states will have a stoichiometry that depends on which oxidation states are present, to ensure overall neutrality. This can be indicated in the name by specifying either the oxidation state of the elements present, or the charge on the ions. Because of the risk of ambiguity in allocating oxidation states, IUPAC prefers direct indication of the ionic charge numbers. These are written as an arabic integer followed by the sign (... , 2−, 1−, 1+, 2+, ...) in parentheses directly after the name of the cation (without a space separating them). For example, FeSO4 is named iron(2+) sulfate (with the 2+ charge on the Fe2+ ions balancing the 2− charge on the sulfate ion), whereas Fe2(SO4)3 is named iron(3+) sulfate (because the two iron ions in each formula unit each have a charge of 3+, to balance the 2− on each of the three sulfate ions). Stock nomenclature, still in common use, writes the oxidation number in Roman numerals (... , −II, −I, 0, I, II, ...). So the examples given above would be named iron(II) sulfate and iron(III) sulfate respectively. For simple ions the ionic charge and the oxidation number are identical, but for polyatomic ions they often differ. For example, the uranyl(2+) ion, UO2+2, has uranium in an oxidation state of +6, so would be called a dioxouranium(VI) ion in Stock nomenclature.
This reaction takes place on the surface of the ribosome, where the C-terminal alpha-helix of the peptide deformylase interacts with a grove between ribosomal proteins uL22 and bL32, and rRNA. For its function this enzyme belongs to the family of hydrolases, those acting on carbon-nitrogen bonds other than peptide bonds, specifically in linear amides. The systematic name of this enzyme class is formyl-L-methionyl peptide amidohydrolase.
Confluent and reticulated papillomatosis (confluent and reticulated papillomatosis of Gougerot and Carteaud, familial cutaneous papillomatosis, familial occurrence of confluent and reticulated papillomatosis) Digitate dermatosis Drug-induced keratoderma Exfoliative dermatitis (dermatitis exfoliativa, erythroderma, red man syndrome) Florid cutaneous papillomatosis Granular parakeratosis (axillary granular parakeratosis, intertriginous granular parakeratosis) Keratolysis exfoliativa (lamellar dyshidrosis, recurrent focal palmar peeling, recurrent palmar peeling) Keratosis punctata of the palmar creases (hyperkeratosis penetrans, hyperkeratosis punctata, keratodermia punctata, keratosis punctata, keratotic pits of the palmar creases, lenticular atrophia of the palmar creases, punctate keratosis of the palmar creases) Meesmann corneal dystrophy Paraneoplastic keratoderma Pityriasis rosea (pityriasis rosea Gibert) Pityriasis rubra pilaris (Devergie's disease, lichen ruber acuminatus, lichen ruber pilaris) Pure hair-nail type ectodermal dysplasia Small plaque parapsoriasis (chronic superficial dermatitis) Tripe palms Xanthoerythrodermia perstans
Sources: en.wikipedia.org
=== Measurement methods === Reported averages vary partly because penile size is affected by erection state, measurement technique and whether the measurement is self-reported or taken by a clinician. In clinical studies, length is commonly measured along the dorsal side from the pubic bone to the tip of the glans, with the pre-pubic fat pad compressed to the bone. Circumference is usually measured at the base or mid-shaft. Stretched flaccid length is also used in clinical assessment, although it is not identical to erect length in all men and can be affected by the amount of traction applied during measurement.
=== Reverse Krebs cycle === The reverse Krebs cycle, also known as the reverse TCA cycle (rTCA) or reductive citric acid cycle, is an alternative to the standard Calvin-Benson cycle for carbon fixation. It has been found in strict anaerobic or microaerobic bacteria (as Aquificales) and anaerobic archea. It was discovered by Evans, Buchanan and Arnon in 1966 working with the photosynthetic green sulfur bacterium Chlorobium limicola. In particular, it is one of the most used pathways in hydrothermal vents by the Campylobacterota. This feature allows primary production in the ocean's aphotic environments, or "dark primary production." Without it, there would be no primary production in aphotic environments, which would lead to habitats without life. The cycle involves the biosynthesis of acetyl-CoA from two molecules of CO2. The key steps of the reverse Krebs cycle are:
== Carcinoma in situ (230–234) == 230 Carcinoma in situ of digestive organs 231 Carcinoma in situ of respiratory system 232 Carcinoma in situ of skin 233 Carcinoma in situ of breast and genitourinary system 234 Carcinoma in situ of other and unspecified sites
Van Zeggeren, F.; Storey, S. H. (1970). The Computation of Chemical Equilibria. Cambridge University Press. Mainly concerned with gas-phase equilibria. Leggett, D. J., ed. (1985). Computational Methods for the Determination of Formation Constants. Plenum Press. Martell, A. E.; Motekaitis, R. J. (1992). The Determination and Use of Stability Constants. Wiley-VCH.
Sources: en.wikipedia.org
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.
Both are synthetic analogues derived from the same parent hormone. Reference descriptions usually characterise afamelanotide as more selective for the MC1R subtype, whereas melanotan-2 is reported to interact with a wider range of melanocortin receptors.
Early studies explored melanocortin signalling and pigmentation, which later led to informal use of the label tanning peptide. That label is not a regulatory category and does not imply approved status for any purpose.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.